Compare Albemarle Corp. (ALB) vs Humana Inc (HUM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Albemarle Corp. vs Humana Inc — how do they compare? Albemarle Corp. trades at $129.93 (market cap $15.22B), while Humana Inc trades at $396.26 (market cap $47.38B). The key difference: Humana Inc is far larger — about 3.1× Albemarle Corp.'s market cap, and Albemarle Corp. pays the higher dividend (1.26%). Which is the better fit depends on your goals.
| ALB | HUM | |
|---|---|---|
Market Cap | $15.22B | $47.38B |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $409.42 |
52-Week Low | $67.30 | $163.67 |
Enterprise Value | $18.24B | $56.42B |
Dividend Yield | 1.26% | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albemarle (ALB) is trading at $129.02, down 4.82% over the past 24 hours amid bearish technical signals. The stock shows mixed fundamentals with a low P/E of 5.12 and negative net income margin of -4.24% for 2025, though Q1 2026 earnings beat expectations. Recent news highlights a focus on debt reduction and energy storage system demand as lithium prices rebound. Cash flow improved in 2025 with net cash flow of $425.77 million, while the balance sheet reflects a debt-to-asset ratio of 19.8%.
The outlook for ALB hinges on lithium price recovery and execution in energy storage markets. Analyst consensus is mixed with a $227.10 price target suggesting significant upside, but risks include volatile lithium markets and ongoing profitability challenges. The stock's current level near key support at $128 may attract value investors, though macroeconomic and commodity pressures remain headwinds.
Humana (HUM) trades at $394.62, down 0.54% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. Revenue growth is strong, reaching $129.66B in 2025, though net income margin has compressed to 0.82%. Recent news highlights expansion through Medicaid contracts and divestitures, alongside legal scrutiny over healthcare costs. The stock shows resilience with consistent earnings beats but faces profitability pressures.
Outlook is mixed: bullish technicals and revenue growth support upside, but margin erosion and legal risks pose challenges. Analysts are cautious with a consensus hold rating and price target of $315, below the current price. Investors should weigh solid fundamentals against regulatory and competitive headwinds for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
